苯拉普利联合缬沙坦治疗糖尿病肾脏病

Combined use of Delaprilt and Valsartan in the treatment of diabetic kidney disease

目的观察苯拉普利、缬沙坦及二者联合用药对糖尿病肾脏病蛋白尿及肾功能的影响。方法糖尿病。肾脏病患者分别给予苯拉普利、缬沙坦、苯拉普利联合缬沙坦，同时控制血糖、血压、血脂，监测治疗前后的血压、血糖、血脂、蛋白尿、肾功能、肾小球滤过率等。结果尽量控制血压、血糖、血脂达标。苯拉普利治疗前尿蛋白为（1．1±0．4）g／24h，治疗后尿蛋白为（0．8±0．2）g／24h。缬沙坦治疗前尿蛋白为（1．2±0．5）g／24h，治疗后尿蛋白为（0．7±0．2）g／24h。联合用药前尿蛋白（1．2±0．8）g／24h，联合用药后尿蛋白下降为（0．5±0．1）g／24h。联合用药前肾小球滤过率为[（83．8±6．6）ml·min^-1（1．73m^2）^-1]，联合用药后肾小球滤过率为[（75．4±7．4）ml·min^-1（1．73m2）。]。结论苯拉普利及缬沙坦联合治疗能更好的减少蛋白尿，保护肾功能。

Objective To observe the effects of Delaprilt,Valsartan,or combined use on proteinuria and renal function of patients with diabetic kidney disease. Methods All patients were divided into Delaprilt group,Valsartan group and combined treatment group. Clinical data were collected at the beginning and 6th month after treatment. Results Urinary protein levels in Delaprilt were（1.1 ± 0. 4） g/ 24 h before treatment, after treatment were （0. 8 ± 0. 2） g/24 h. Urinary protein levels in Valsartan groups were （1.2 ± 0. 5） g/24 h before treatment,after treatment were （0.7 ± 0. 2） g/24 h,and those in combined treatment group were （1.2 ± 0. 8） g/24 h before treatment, after treatment were （0. 5 ± 0. 1） g/24 h. Glomerular filtration rate in combined treatment group were [（83. 8 ± 6. 6） ml·min^-1（1. 73 m^2 ） ^- 1 ] before treatment, after treatment were [ （75.4 ± 7. 4）ml·min^-1. （1.73 m^2 ） ^- 1 ]. Conclusions Combined used of Delaprilt and Valsartan can effectively alleviate proteinuria and protect renal function.